File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Local antimicrobial therapy after initial periodontal treatment: A randomized clinical trial comparing three biodegradable sustained release polymers

TitleLocal antimicrobial therapy after initial periodontal treatment: A randomized clinical trial comparing three biodegradable sustained release polymers
Authors
Issue Date2002
PublisherBlackwell Munksgaard. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CPE
Citation
Journal Of Clinical Periodontology, 2002, v. 29 n. 6, p. 540-550 How to Cite?
AbstractAim: The aim of this single-blind, randomized, parallel-designed clinical trial (RCT) was to evaluate the clinical and microbiological effects of three sustained-release biodegradable polymers delivered into periodontal pockets following initial periodontal therapy. Methods: Forty-seven patients (28 females and 19 males) with a mean age of 51 years (range 29-71) underwent a periodontal examination at baseline (i.e. Week 0) and after 18 weeks. This included the assessment of the Plaque Index (PlI), Bleeding on Probing (BOP), Pocket Probing Depths (PPD) and Probing Attachment Levels (PAL) at six sites per tooth. Two to 4 months prior to baseline, all subjects had received initial periodontal therapy including motivation, instruction in oral hygiene practices and full-mouth scaling and root planing. At the treatment appointment (i.e. Week 2), the patients were randomly assigned to receive either Atridox™, Elyzol® Dental Gel or PerioChip® at all residual periodontal pockets with a probing depth ≥ 5 mm and concomitant BOP. In accordance with the manufacturer's recommendations, Elyzol® Dental Gel was applied for a second time 7 days later. In addition to the clinical evaluation, subgingival microbiological samples were collected prior to treatment (i.e. Week 2) and at Weeks 4 and 18. Analysis of variance/covariance was used to evaluate changes from baseline to Week 18 for the clinical parameters. Results: Between the baseline and 18-week examinations, subjects treated with Atridox showed a significantly greater gain in mean PAL of 0.33 mm ± 0.09 (SD) than subjects treated with Elyzol® Dental Gel [0.03 mm ± 0.09 (SD)] (p = 0.03). However, the gain in PAL of 0.16 mm ± 0.10 (SD) found after PerioChip® application did not differ significantly from that obtained following the application of Atridox™ (p = 0.27). Of the sites treated with Atridox™, 42% gained ≥1 mm PAL and 9% ≥ 2 mm PAL as opposed to the sites treated with Elyzol® Dental Gel, in which 34% gained ≥ 1 mm PAL and 8% gained ≥ 2 mm PAL. Of the sites treated with PerioChip®, 36% gained ≥ 1 mm and 6% gained ≥ 2 mm PAL following a completed initial periodontal therapy. Conclusions: The application of the three biodegradable sustained release devices tested following initial periodontal therapy resulted in a statistically significant gain in mean PAL for Atridox™ and a significant reduction in PPD for all three devices during the study period. Furthermore, when sites treated with Atridox™ were compared with sites treated with Elyzol®, a significant difference in mean PAL gain (0.3 mm) was observed. © Blackwell Munksgaard, 2002.
Persistent Identifierhttp://hdl.handle.net/10722/154199
ISSN
2015 Impact Factor: 3.915
2015 SCImago Journal Rankings: 1.848
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorSalvi, GEen_US
dc.contributor.authorMombelli, Aen_US
dc.contributor.authorMayfield, Len_US
dc.contributor.authorRutar, Aen_US
dc.contributor.authorSuvan, Jen_US
dc.contributor.authorGarrett, Sen_US
dc.contributor.authorLang, NPen_US
dc.date.accessioned2012-08-08T08:23:50Z-
dc.date.available2012-08-08T08:23:50Z-
dc.date.issued2002en_US
dc.identifier.citationJournal Of Clinical Periodontology, 2002, v. 29 n. 6, p. 540-550en_US
dc.identifier.issn0303-6979en_US
dc.identifier.urihttp://hdl.handle.net/10722/154199-
dc.description.abstractAim: The aim of this single-blind, randomized, parallel-designed clinical trial (RCT) was to evaluate the clinical and microbiological effects of three sustained-release biodegradable polymers delivered into periodontal pockets following initial periodontal therapy. Methods: Forty-seven patients (28 females and 19 males) with a mean age of 51 years (range 29-71) underwent a periodontal examination at baseline (i.e. Week 0) and after 18 weeks. This included the assessment of the Plaque Index (PlI), Bleeding on Probing (BOP), Pocket Probing Depths (PPD) and Probing Attachment Levels (PAL) at six sites per tooth. Two to 4 months prior to baseline, all subjects had received initial periodontal therapy including motivation, instruction in oral hygiene practices and full-mouth scaling and root planing. At the treatment appointment (i.e. Week 2), the patients were randomly assigned to receive either Atridox™, Elyzol® Dental Gel or PerioChip® at all residual periodontal pockets with a probing depth ≥ 5 mm and concomitant BOP. In accordance with the manufacturer's recommendations, Elyzol® Dental Gel was applied for a second time 7 days later. In addition to the clinical evaluation, subgingival microbiological samples were collected prior to treatment (i.e. Week 2) and at Weeks 4 and 18. Analysis of variance/covariance was used to evaluate changes from baseline to Week 18 for the clinical parameters. Results: Between the baseline and 18-week examinations, subjects treated with Atridox showed a significantly greater gain in mean PAL of 0.33 mm ± 0.09 (SD) than subjects treated with Elyzol® Dental Gel [0.03 mm ± 0.09 (SD)] (p = 0.03). However, the gain in PAL of 0.16 mm ± 0.10 (SD) found after PerioChip® application did not differ significantly from that obtained following the application of Atridox™ (p = 0.27). Of the sites treated with Atridox™, 42% gained ≥1 mm PAL and 9% ≥ 2 mm PAL as opposed to the sites treated with Elyzol® Dental Gel, in which 34% gained ≥ 1 mm PAL and 8% gained ≥ 2 mm PAL. Of the sites treated with PerioChip®, 36% gained ≥ 1 mm and 6% gained ≥ 2 mm PAL following a completed initial periodontal therapy. Conclusions: The application of the three biodegradable sustained release devices tested following initial periodontal therapy resulted in a statistically significant gain in mean PAL for Atridox™ and a significant reduction in PPD for all three devices during the study period. Furthermore, when sites treated with Atridox™ were compared with sites treated with Elyzol®, a significant difference in mean PAL gain (0.3 mm) was observed. © Blackwell Munksgaard, 2002.en_US
dc.languageengen_US
dc.publisherBlackwell Munksgaard. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CPEen_US
dc.relation.ispartofJournal of Clinical Periodontologyen_US
dc.subject.meshActinobacillus Actinomycetemcomitans - Growth & Developmenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAnalysis Of Varianceen_US
dc.subject.meshAnti-Bacterial Agents - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshAnti-Infective Agents, Local - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshBiodegradation, Environmentalen_US
dc.subject.meshChlorhexidine - Administration & Dosage - Analogs & Derivatives - Therapeutic Useen_US
dc.subject.meshColony Count, Microbialen_US
dc.subject.meshDelayed-Action Preparationsen_US
dc.subject.meshDental Plaque Indexen_US
dc.subject.meshDoxycycline - Administration & Dosage - Analogs & Derivatives - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshFusobacterium - Growth & Developmenten_US
dc.subject.meshGingival Hemorrhage - Drug Therapyen_US
dc.subject.meshGlycerides - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMetronidazole - Administration & Dosage - Analogs & Derivatives - Therapeutic Useen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPeriodontal Attachment Loss - Drug Therapyen_US
dc.subject.meshPeriodontal Pocket - Drug Therapy - Microbiologyen_US
dc.subject.meshPeriodontitis - Drug Therapy - Microbiologyen_US
dc.subject.meshPorphyromonas - Growth & Developmenten_US
dc.subject.meshPrevotella - Growth & Developmenten_US
dc.subject.meshSesame Oil - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshSingle-Blind Methoden_US
dc.subject.meshTreatment Outcomeen_US
dc.titleLocal antimicrobial therapy after initial periodontal treatment: A randomized clinical trial comparing three biodegradable sustained release polymersen_US
dc.typeArticleen_US
dc.identifier.emailLang, NP:nplang@hkucc.hku.hken_US
dc.identifier.authorityLang, NP=rp00031en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1034/j.1600-051X.2002.290611.xen_US
dc.identifier.pmid12296782-
dc.identifier.scopuseid_2-s2.0-0036598367en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0036598367&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume29en_US
dc.identifier.issue6en_US
dc.identifier.spage540en_US
dc.identifier.epage550en_US
dc.identifier.isiWOS:000178184000011-
dc.publisher.placeDenmarken_US
dc.identifier.scopusauthoridSalvi, GE=35600695300en_US
dc.identifier.scopusauthoridMombelli, A=7006180872en_US
dc.identifier.scopusauthoridMayfield, L=7004160753en_US
dc.identifier.scopusauthoridRutar, A=6602283506en_US
dc.identifier.scopusauthoridSuvan, J=19637686000en_US
dc.identifier.scopusauthoridGarrett, S=7102507165en_US
dc.identifier.scopusauthoridLang, NP=7201577367en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats